Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...
Delonix Bioworks announced that DX-104, its Group B meningococcal (MenB) vaccine candidate, has received clinical...
Chengdu Olymvax Biopharmaceuticals Inc. and Delonix Bioworks Co., Ltd. today announced a strategic collaboration and...
China-based Delonix Bioworks Ltd., a developer of genetically engineered bacterial vaccines, has entered into a...